{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:37Z","timestamp":1792699177562,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974369"],"award-info":[{"award-number":["81974369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2019YFC1316000"],"award-info":[{"award-number":["2019YFC1316000"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.eclinm.2022.101480","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:29:44Z","timestamp":1654262984000},"page":"101480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial"],"prefix":"10.1016","volume":"49","author":[{"given":"Yi","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-0128","authenticated-orcid":false,"given":"Jianwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1376-6000","authenticated-orcid":false,"given":"Jiayu","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-8026","authenticated-orcid":false,"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eclinm.2022.101480_bib0001","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","article-title":"Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?","volume":"20","author":"Ng","year":"2015","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.eclinm.2022.101480_bib0002","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101480_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.eclinm.2022.101480_bib0004","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101480_bib0005","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/annonc\/mdx315","article-title":"A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin","volume":"28","author":"Bossi","year":"2017","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.eclinm.2022.101480_bib0006","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101480_bib0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","article-title":"Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice","volume":"4","author":"Hesketh","year":"1999","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101480_bib0008","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","article-title":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101480_bib0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.eclinm.2022.101480_bib0010","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2022.101480_bib0011","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1073\/pnas.160099797","article-title":"Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids","volume":"97","author":"Bianchi","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101480_bib0012","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/eji.200635873","article-title":"Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE","volume":"36","author":"Chen","year":"2006","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.eclinm.2022.101480_bib0013","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101480_bib0014","first-page":"423","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101480_bib0015","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101480_bib0016","first-page":"1217","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial","volume":"19","author":"Celio","year":"2011","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101480_bib0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101480_bib0018","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","article-title":"Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model","volume":"64","author":"Pollera","year":"1989","journal-title":"Cancer"},{"issue":"2-3","key":"10.1016\/j.eclinm.2022.101480_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","article-title":"Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron","volume":"28","author":"du Bois","year":"1992","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101480_bib0020","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101480_bib0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the national cancer institute of canada clinical trials group","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101480_bib0022","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101480_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.eclinm.2022.101480_bib0024","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101480_bib0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1471-4892(02)00227-8","article-title":"Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction","volume":"2","author":"Andrews","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.eclinm.2022.101480_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2013.09.075","article-title":"Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders","volume":"722","author":"Bashashati","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.eclinm.2022.101480_bib0027","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0959-8049(02)00674-3","article-title":"Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists","volume":"39","author":"Hesketh","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2022.101480_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fphar.2017.00019","article-title":"Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management","volume":"8","author":"Rapoport","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101480_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-509X.31164","article-title":"Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting","volume":"44","author":"Girish","year":"2007","journal-title":"Indian J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2022.101480_bib0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/17425255.1.1.143","article-title":"New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron","volume":"1","author":"Tonini","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101480_bib0031","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2022.101480_bib0032","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101480_bib0033","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/cas.14757","article-title":"5HT(3) RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer","volume":"112","author":"Hayashi","year":"2021","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.eclinm.2022.101480_bib0034","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2022.101480_bib0035","series-title":"Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults","author":"McDonagh","year":"2010"},{"issue":"9370","key":"10.1016\/j.eclinm.2022.101480_bib0036","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(03)13365-X","article-title":"Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer","volume":"361","author":"Guttuso","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101480_bib0037","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/intimm\/dxh230","article-title":"Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoids","volume":"17","author":"Igarashi","year":"2005","journal-title":"Int Immunol"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101480_bib0038","first-page":"587","article-title":"Chronic elevation of plasma corticosterone causes reductions in the number of cycling cells of the B lineage in murine bone marrow and induces apoptosis","volume":"80","author":"Garvy","year":"1993","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101480_bib0039","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/en.2013-1473","article-title":"Analysis of glucocorticoid receptors and their apoptotic response to dexamethasone in male murine B cells during development","volume":"155","author":"Gruver-Yates","year":"2014","journal-title":"Endocrinology"},{"issue":"15","key":"10.1016\/j.eclinm.2022.101480_bib0040","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-03-631580","article-title":"Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice","volume":"126","author":"Bruscoli","year":"2015","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:12:38Z","timestamp":1762888358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022002103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"alternative-id":["S2589537022002103"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101480","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101480"}}